Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of antibody–drug conjugates.

Even with cancer-associated antigens studding ... strategy for treating patients with tumors with high heterogeneity. Patterns of antigen architectures in patient tumors correlated with T cell ...

This target antigen heterogeneity means that even a CAR T-cell therapy with two or three targets results in immune escape. Another significant obstacle is the immune-suppressive tumor ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

Chimeric antigen receptor (CAR ... we don't have enough of a therapeutic effect before we get toxicity." Tumor-cell heterogeneity has represented a major obstacle to the development of CAR ...